Ravi Jasuja
Chief Scientific Officer XYone Therapeutics
Dr. Ravi Jasuja is Co-Founder and Chief Scientific Officer of XYone Therapeutics and Director of Translational Research and Discovery (RPMH), Aging and Metabolism at Brigham and Women’s Hospital, Harvard Medical School. His translational work spans two decades – from redefining hormone-receptor biophysics and developing novel diagnostics for androgen disorders in aging to translational oncology for first-in-class MUC1-C–targeted therapeutics for solid tumors. Trained as a Belfer Fellow in Biophysics at Albert Einstein College of Medicine, he brings deep expertise in bridging molecular discovery to clinical application across endocrine dysregulation and immuno-oncology
Seminars
Tuesday 13th October 2026
Unlocking MUC1-C for ADC Therapy: Translational Innovation of XYA01/02 from Preclinical Validation to Clinical Forefront
12:00 pm
- Contextualizing suboptimal MUC1-N targeting properties to demonstrate benefits to MUC1-C subunit as an ADC target
- Exploring preclinical PDX safety and efficacy for XYA01/02 leading to NCI NExT program selection and IND enabling development
- Evaluating XYA01/02 trial design positioning for differentiated impact across MUC1-C-expressing epithelial carcinomas versus existing anti-MUC1 ADCs
